Anti-CD38 immunotherapy treatment for multiple myeloma

Triple class refractory multiple myeloma

Managing high-risk/MRD positive and standard-risk/MRD myeloma

Minimum residual disease techniques in myeloma

Identifying and treating high-risk/MRD positive newly diagnosed multiple myeloma

High-risk SMM imaging and NDMM treatment

Rescue after daratumumab failure

MRD-driven strategies and novel immunotherapies for multiple myeloma

How to approach pain management in myeloma patients

Refractoriness and retreatment in the era of lenalidomide and mABs in the frontline myeloma setting